Stelac Advisory Services’s Apellis Pharmaceuticals APLS Stock Holding History

Stelac Advisory Services’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,520	Closed	-$222K	–	169
2026 Q1	$222K	Hold	5,520	–	–	0.04%	123
2025 Q4	$139K	Hold	5,520	–	–	0.05%	98
2025 Q3	$125K	Buy	+5,520	New	+$129K	0.04%	101
2025 Q2	–	Sell	-5,520	Closed	-$121K	–	105
2025 Q1	$121K	Hold	5,520	–	–	0.05%	92
2024 Q4	$176K	Hold	5,520	–	–	0.07%	83
2024 Q3	$159K	Hold	5,520	–	–	0.06%	88
2024 Q2	$212K	Hold	5,520	–	–	0.09%	77
2024 Q1	$324K	Hold	5,520	–	–	0.15%	59
2023 Q4	$330K	Hold	5,520	–	–	0.18%	57
2023 Q3	$210K	Hold	5,520	–	–	0.11%	77
2023 Q2	$503K	Hold	5,520	–	–	0.22%	87
2023 Q1	$364K	Hold	5,520	–	–	0.16%	101
2022 Q4	$285K	Buy	+5,520	New	+$293K	0.13%	116

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Stelac Advisory Services's APLS Position: Q2 2026 in Review

Stelac Advisory Services sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 5,520 shares — an estimated $222K sold.

Stelac Advisory Services first reported a position in APLS in Q4 2022 and held it in 13 quarters. The position peaked at $503K in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Stelac Advisory Services reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Stelac Advisory Services sold 5,520 Apellis Pharmaceuticals shares in Q2 2026, an estimated $222K.
Stelac Advisory Services first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 13 quarters.
Stelac Advisory Services's Apellis Pharmaceuticals position peaked at $503K in Q2 2023.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Stelac Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.